Introduction
The development of a chemotherapy-resistant phenotype is a major cause of treatment failure in breast cancer and other malignancies. The drug-resistant phenotype has been linked to a number of molecular alterations in the tumor cells, including alterations in cellular transport and metabolism of cytotoxic drugs, mutations of the p53 tumor suppressor gene, and altered levels of DNA topoisomerases (reviewed in Schecter et al., 1992; Takano et al., 1992) . In addition, recent studies suggest that certain growth factors and cytokines (e.g., insulin-like growth factor-1 and interleukin-1b) can suppress apoptosis of target cell populations, although the mechanism(s) are not well understood (Resnico et al., 1995; Friedlander et al., 1996) . Apoptosis is a major mechanism by which DNA-damaging drugs, ionizing radiation, and other cytotoxic agents result in tumor cell death (reviewed in Reed, 1995; Wertz and Hanley, 1996) . Therefore, the abnormal accumulation of certain cytokines within tumors may also contribute to a drug-and radiation resistant phenotype.
Scatter factor (SF) (also called hepatocyte growth factor) is a multifunctional cytokine whose activities include stimulation of epithelial cell motility and invasiveness as well as induction of angiogenesis (reviewed in Rosen et al., 1994b) . Its receptor is a transmembrane tyrosine kinase encoded by a protooncogene (c-Met) (Bottaro et al., 1991) . Overexpression of SF induces in various experimental tumor models, including a human breast cancer model, causes enhanced in vivo tumorigenicity, tumor growth, and angiogenesis (Rong et al., 1992; Lamszus et al., 1997; Laterra et al., 1997) . In addition, studies of clinical human breast cancer specimens indicate that SF and cMet receptor are over-expressed during the progression from benign proliferative lesions or non-invasive tumors to invasive carcinomas (Yao et al., 1996; Jin et al., 1997) . Within the invasive cancer group, the SF content was strongly correlated with the content of von Willebrand's factor, an endothelial cell marker, suggesting a relationship between SF and tumor vascularity (Yao et al., 1996) . Moreover, the SF content of tumor extracts was found to be a powerful independent indicator of prognosis in invasive breast cancer (Yamashita et al., 1994) .
Several recent studies suggest that SF may modulate the process of apoptosis. For example, SF was found to protect Madin-Darby canine kidney (MDCK) renal tubular epithelial cells against apoptosis induced by detachment of cells from their substrate (Frisch and Francis, 1994) ; and infusion of SF after mitogenic activation of liver ductal epithelium by the hepatocarcinogen 2-acetylamino¯uorene stimulated motility and inhibited apoptosis of ductal and periductal cells (Nagy et al., 1996) . Over-expression of the antiapoptotic protein Bag-1 in MLP-29 liver progenitor cells enhanced the ability of SF to inhibit apoptosis induced by protein kinase inhibitor staurosporine, although the mechanism is unclear (Bardelli et al., 1996) ; and Tpr-Met, a constitutively active oncogenic form of c-Met, also enhanced protection against staurosporine (Amicone et al., 1997) .
Based on the above considerations, we sought to test the hypothesis that SF might function to protect breast cancer cells against apoptosis induced by DNAdamaging agents, including agents commonly utilized in breast cancer therapy.
Results

SF protects MDA-MB-453 human breast cancer cells against apoptosis induced by a variety of DNA-damaging agents
Initially, studies were performed to evaluate the ability of SF to rescue MDA-MB-453 cells from apoptosis induced by DNA-damaging agents. We found that pretreatment with 100 ng/ml of SF for 48 h markedly protected cells against apoptotic DNA fragmentation induced by exposure to adriamycin (ADR) (5 mM 6 1 h), X-rays (650 cGy), and ultraviolet (UV) radiation (10 J/m 2 ) (see Figure 1a) . In additional studies, SF also protected these cells against apoptosis caused by other agents, including cis-platinum, nitrogen mustard and taxol (data not shown).
SF-mediated protection of MDA-MB-453 cells against ADR was dependent upon the dose of SF as well as the pre-treatment time. In several dierent experiments using a 48 h incubation time, we found that protection required more than 10 ng/ml of SF and became maximal or near maximal at 75 ± 100 ng/ml of SF (see Figure 1b , left). A dose of 300 ng/ml of SF did not yield additional protection, as compared with 100 ng/ml (data not shown). Pre-incubation time course studies were performed utilizing a dose of 100 ng/ml of SF. These experiments revealed little or no protection when SF was added only at the same time of ADR treatment and thereafter (see Figure 1b , right) (compare`0 h + ADR' vs`ADR'). The degree of cytoprotection increased with the pre-incubation times, reaching a maximum when cells were incubated with SF for at least 48 h before exposure to ADR. Studies of SF-mediated protection against apoptosis induced by X-rays gave similar ®ndings (data not shown). Therefore, a 48 h pre-treatment with 100 ng/ml of SF was selected for subsequent experiments in this study.
SF protects EMT6 mouse mammary tumor cells and Madin-Darby canine kidney (MDCK) renal tubular epithelial cells against apoptosis
We tested the ability of SF to protect two other cell lines, EMT6 and MDCK, against apoptosis induced by the same three DNA-damaging agents. Both of these cell lines express the c-Met receptor and are responsive to SF in other bioassays (Rosen et al., 1994a; Stoker et al., 1987) . Similar to MDA-MB-453, SF markedly protected EMT6 (Figure 2a ) as well as MDCK ( Figure  2b ) against these agents. On the other hand, SF did not protect MDA-MB-231 human breast cancer cells against DNA-damaging agents, despite the fact that these cells express c-Met and are SF-responsive in bioassays of cell motility . Thus, the expression of a functional c-Met receptor is not sucient for SF-mediated protection against apoptosis.
SF protection requires a functional c-Met receptor
To determine if SF-mediated protection of target cells requires the c-Met receptor, experiments similar to those described above were performed in the absence or presence of NK1, a fragment of the the SF a-chain that exhibits high anity binding to c-Met and speci®cally antagonizes some of the biologic responses to SF (Lokker et al., 1992) . Pre-incubation with NK1 (300 ng/ml) for 48 h before ADR treatment did not protect MDA-MB-453 cells against ADR-induced apoptosis. However, the same dose of NK1 ablated the cytoprotective activity of 100 ng/ml of SF (Figure   b a Figure 1 Scatter factor (SF) protects MDA-MB-453 human breast cancer cells against apoptosis induced by adriamycin (ADR), X-rays and ultraviolet (UV) radiation. (a) Subcon¯uent proliferating cells were pre-treated + SF (100 ng/ml 6 48 h) and then treated + ADR (5 mM 6 1 h), X-rays (6.5 Gy) or UV radiation (10 J/m 2 ). (b) Cells were pre-treated with various concentrations of SF for 48 h and then treated with ADR (left); cells were pre-treated with 100 ng/ml of SF for dierent times before treatment with ADR (right). Twenty-four hours after drug treatment or irradiation, the cells were harvested for DNA fragmentation assays (see Materials and methods). Assays pictured are from representative experiments that were repeated at least twice with similar results 3a). Similar results were obtained using EMT6 cells (see Figure 3b ). Taken together with the above results, these data suggest that a functional c-Met receptor is necessary but not sucient for the anti-apoptotic eect of SF.
Pre-treatment with SF enhances viability, clonogenic survival, and metastatic capacity of cells treated with ADR
The MTT assay of cell viability is a spectrophotometric assay that relies on the capacity of intact mitochondria to convert MTT to formazan (Alley et al., 1988) . As illustrated in Figure 4a , pre-treatment with SF markedly enhanced the viability of MDA-MB-453 cells exposed to dierent doses of ADR, as demonstrated by increased levels of MTT dye conversion. Based on the MTT assay, cells pre-treated with SF were about ®vefold more resistant to ADR (IC 50 = 2.5 mM of ADR) than were sham pre-treated control cells (IC 50 = 0.45 mM of ADR).
This enhancement of cell viability by SF was also demonstrated in assays of clonogenic cell survival. Thus, prior treatment with 100 ng/ml for 48 h resulted in signi®cantly increased cell survival following treatment with 1.0 or 5.0 mM ADR (see Table 1a ). A representative photograph illustrating colony formation of MDA-MB-453 cells treated + SF (100 ng/ml 6 48 h) and + ADR (5 mM 6 1 h) is shown in Figure  4b . Note that SF by itself had little eect on the colony number or morphology. There were no colonies of surviving cells after treatment with ADR alone. Many colonies of surviving cells were detected after treatment with SF+ADR, although the number and size of these colonies was less than that of control cells.
Similar to MDA-MB-453, pre-treatment with SF also signi®cantly enhanced the in vitro clonogenic a b Figure 2 Scatter factor protects EMT6 mouse mammary tumor cells and Madin-Darby canine kidney (MDCK) epithelial cells against apoptosis induced by DNA-damaging agents. EMT6 cells (a) and MDCK cells (b) were pre-treated + SF (100 ng/ml 6 48 h) and then exposed to ADR (5 mM 6 1 h), X-rays (6.5 Gy) or UV radiation (10 J/m 2 ). Cells were harvested for DNA fragmentation assays 24 h after drug treatment or irradiation. Assays shown are from representative experiments that were conducted at least twice, with similar results a b Figure 3 Reversal of scatter factor-mediated protection of breast cancer cells against adriamycin-induced apoptosis by the speci®c c-Met receptor antagonist NK1. Subcon¯uent proliferating cultures of MDA-MB-453 human breast cancer cells (a) and EMT6 mouse mammary tumor cells (b) were pre-treated with SF (100 ng/ml) and/or NK-1 (300 ng/ml) for 48 h; exposed to ADR (5 mM 6 1 h); and incubated for 24 h in ADR-free medium. Cells were then harvested for standard DNA fragmentation assays. PCR markers were used as DNA size markers (b) survival of EMT6 treated with ADR (see Table 1b ). We also determined the eects of treatment of EMT6 cells with SF and ADR on their ability to form lung colonies in isogeneic host mice. The formation of lung nodules by intravenously injected EMT6 cells has been utilized as a model system for the entrapment and growth phases of the metastatic process (Rockwell, 1981) . We previously reported that in vitro pretreatment of EMT6 cells with SF induced a significant increase in lung colony formation, without aecting in vitro clonogenic survival, DNA synthesis, cell proliferation, or cell size (Rosen et al., 1994a) . Consistent with that study, we found that pre-treatment with SF alone caused about a two-fold increase in lung colony formation, with little or no eect on in vitro clonogenic survival (Table 1b) . Although the cell yields from dishes treated with (SF+ADR) were similar to those of cells treated with ADR alone, the (SF+ADR)-treated cells yielded signi®cantly greater in vitro clonogenic survival and in vivo lung colony formation as compared with ADR-treated cells.
Alterations in the levels of apoptosis-regulatory proteins following treatment of MDA-MB-453 cells with SF and ADR
The requirement of prolonged pre-incubation with SF for protection against apoptosis suggests that maximal protection may require new protein synthesis. To test the hypothesis that SF-mediated protection of MDA-MB-453 involves alterations in the levels of key apoptosis-regulatory proteins, we examined the eects of SF and ADR on the levels of a panel of gene products that may directly or indirectly modulate the process of apoptosis. Cells were pre-incubated without or with SF (100 ng/ml 6 48 h) and were then treated + ADR (5 mM 6 1 h). Proteins were quantitated by Western blotting of equal aliquots (100 mg protein/lane) of lysates of cells harvested 24 h after ADR treatment. Representative results from these experiments are shown in Figure 5 .
MDA-MB-453 cells were reported to contain a 30-bp deletion in exon 11 of the p53 gene that results in a loss of p53 expression (Runnebaum et al., 1991) . Consistent with this report, Western blots using an antibody that detects both wild-type and mutant p53 (pAb1801), revealed a low basal p53 level that did not increase in response to ADR (Figure 5a and p21 levels were lowest in cells treated with (SF+ADR).
The proto-oncogene Bcl-2 is the prototype of a family of proteins that exert anti-apoptotic or proapoptotic activity via the formation of hetero-and homodimers (Vaux et al., 1988) . Western blots for Bcl-2 revealed decreased expression of Bcl-2 protein in ADR-treated cells relative to controls (Figure 5a ). However, pre-treatment with SF had little or no eect on Bcl-2 levels in control or ADR-treated cells. The 32 ± 34 kDa Bcl-X L protein is another anti-apoptotic member of the Bcl-2 family (Boise et al., 1993) ; on the other hand, Bcl-X S , a truncated form of Bcl-X with a deletion of 63 amino acids (residues 126 ± 188), exhibits strong pro-apoptotic activity (Minn et al., 1996) .
Western blotting was performed using a monoclonal antibody that detects an N-terminal epitope present in both long (Bcl-X L ) and short (Bcl-X S ) isoforms of Bcl-X (S-18, Santa Cruz Biotechnology). These studies revealed an ADR-induced decrease in the 32 ± 34 kDa Bcl-X L protein. The two Bcl-X L bands visible in the Western probably represent isoforms or dierentially glycosylated/phosphorylated forms of the Bcl-X L protein. Pre-treatment with SF ablated the ADRinduced decrease in the levels of Bcl-X L . The Bcl-X S isoform, which should be 7 ± 8 kDa smaller in M r than Bcl-X L , was not detected in MDA-MB-453 cells.
Over-expression of Bax-a, the major isoform of Bax, induces apoptosis (Oltvai et al., 1994) . Isoforms of Bax-a are generated by alternative mRNA splicing (Bax-b, delta, tau) . Some isoforms (Bax-b, Bax-delta) lack the C-terminal membrane targeting sequence; and their roles in modulating apoptosis are unclear (Apte et al., 1995) . Western blotting with a monoclonal antibody against the C-terminal region of Bax revealed two bands of the approximate M r of Bax. SF treatment resulted in a decrease in the higher M r band and a parallel increase in lower M r band. We believe that the upper band is Bax-a, since it comigrates with Bax expressed by MCF-7 cells, which lack the lower M r band. The other band might represent another isoform or a contaminating band. The pro-apoptotic proteins Bad (Yang et al., 1995) and Bak (Chittender et al., 1995) were constitutively expressed by MDA-MB-453 cells. Levels of these proteins were similar or slightly decreased in cells treated with (SF+ADR) as compared with ADR alone.
Over-expression of c-Myc in growth factor-deprived cells can induce apoptosis, both by p53-dependent and p53-independent mechanisms (Packham et al., 1996; Lenahan and Ozer, 1996) . We examined the protein levels of various members of the c-Myc transcriptional network (HuÈ rlin et al., 1993 (HuÈ rlin et al., , 1994 in MDA-MB-453 cells (see Figure 5b ). SF alone and ADR alone each induced an increase in c-Myc levels; but pre-treatment with SF blocked the ADR-induced increase in c-Myc levels. The c-Myc binding partner Max exists in two protein isoforms, p22Max L and p21Max S , that dier by a 9 amino acid deletion in the N-terminus of Max S . The functional signi®cance of these isoforms is unclear, but a recent study suggests that Max L and Max S may dierentially regulate the processes of cell proliferation and apoptosis (Zhang et al., 1997) . Under basal conditions, MDA-MB-453 cells expressed mostly p21Max S . However, ADR induced the appearance of a p22Max L band. In cells treated with (SF+ADR), there was a p21Max S band as well as two other bands, each with slightly higher M r than p22Max L . These may represent phosphorylated forms of Max L .
Western blotting for isoforms of the Max binding partner Mad revealed no change in Mad1 induced by SF or ADR. ADR induced modest decreases in Mad2 and Mad3 levels; and these decreases were blocked by SF. We were not able to detect any Mad4 in MDA-MB-453 cells. Thus, our ®ndings suggest that cells treated with (SF+ADR) have a decrease in the ratio of c-Myc/Mad relative to cells treated with ADR alone.
The breast and ovary cancer susceptibility gene BRCA1 encodes a 220 kDa protein that may play roles in regulation of apoptosis, cell cycle progression, and DNA repair Rao et al., 1996; Scully et al., 1997) . We found that SF and ADR by themselves had relatively little eect on BRCA1 protein levels (Figure 5a ). However, the levels of BRCA1 appeared to be signi®cantly lower in cells treated with (SF+ADR) as compared with cells treated with ADR alone. Western blot analysis of MDA-MB-453 human breast cancer cells treated with scatter factor and/or ADR. Subcon¯uent proliferating cells were treated + SF and then + ADR as described in Figure 1a legend. Cells were incubated for another 24 h prior to extraction of total cell protein. by SF against ADR-or X-ray induced apoptosis ( Figure 6a ). In addition, two clones of MDA-MB-231 transfected with SF showed similar degrees of apoptosis induced by various cytotoxic agents (ADR, nitrogen mustard, cis-platinum, taxol) as compared with two control clones that do not produce SF (data not shown). MDA-MB-231 cells are more somewhat resistant to ADR than MDA-MB-453 cells: thus, an adriamycin dose of 10 mM 6 1 h produces about the same amount of apoptosis in MDA-MB-231 as does 5 mM 6 1 h in MDA-MB-453. We examined expression in MDA-MB-231 cells of some of the apoptosis-regulatory proteins previously studied, particularly focusing on proteins for which SFinduced alterations had been observed in MDA-MB-453 cells. Cells were treated + SF (100 ng/ml 6 48 h), then + ADR (10 mM 6 1 h), and then incubated for 24 h. MDA-MB-231 cells express high levels of a mutant p53; and the p53 protein levels were not signi®cantly aected by SF or ADR (Figure 6b Bcl-X L protein levels, these ®ndings implicate Bcl-X L as a possible mediator through which SF protects MDA-MB-453 human breast cancer cells against ADR.
SF-induced alterations in
SF does not alter the cell cycle distribution of MDA-MB-453 cells
Prior studies revealed that, as is true for many carcinoma cell lines, SF has little or no eect on the rate of proliferation of MDA-MB-453 cells (data not shown). We also determined the eect of SF on the cycle distribution of MDA-MB-453 cells by¯ow cytometry of propidium iodide-stained cell nuclei. As expected, ADR induced a sub-G1 peak consistent with apoptotic DNA-fragmentation, while this peak was reduced in cells treated with (SF+ADR) (Figure 8 ). ADR induced an increase in the fraction of cells in G2-M and a decrease in the fraction of cells in S, consistent with a G2 arrest in cells missing the p53-mediated G1 DNA-damage checkpoint. However, other than the sub-G1 peak, the DNA histogram of cells treated with (SF+ADR) was similar to that of cells treated with ADR alone, suggesting that cell cycle alterations were not a major factor in SF-mediated protection.
Discussion
We report that SF protects MDA-MB-453 human breast cancer cells and other cell lines against apoptosis induced by DNA-damaging agents, including cytotoxic agents used in cancer therapy. The anti-apoptotic activity of SF required signal transduction from the c-Met receptor, since little or no cytoprotection was observed in the presence of NK1, a speci®c c-Met receptor blocker. Maximal SF-mediated protection required a prolonged exposure of at least 48 h, suggesting that the protective mechanism requires new protein synthesis. Protection by SF against apoptosis was associated with a reduction in adriamycin-induced cytotoxicity and a signi®cant increase in clonogenic cell survival. Furthermore, studies utilizing the EMT6 mouse mammary tumor system revealed that pre-treatment with SF signi®cantly enhanced the capacity of ADR-treated tumor cells to colonize the lungs. As we reported earlier (Rosen et al., 1994a) , SF alone enhanced the ability of circulating EMT6 cells to form lung colonies. This ®nding may be an in vivo manifestation of the ability of SF to protect epithelial cells against apoptosis triggered by detachment from their substrate (Frisch and Francis, 1994) . Our ®ndings suggest that the protective action of SF may result in a chemoresistant phenotype by blocking apoptotic cell death. All of the dierent assays of cell survival and cytotoxicity revealed SF mediated cytoprotection. However, the magnitude of the change in fractional cell survival+SF at 5 mM ADR appears to be less marked in the MTT assays (Figure 4a ) than that observed in clonogenic survival assays (Table 1A and Figure 4b ); and the cell cycle assays showed only a small amount of fragmented apoptotic DNA (sub-G1 peak) (Figure 8 ). The most likely explanation is that these assays measure dierent end-points; and these end-points are measured at dierent times post treatment with DNA-damaging agents. First, in the MTT assay, the end-point is the ability of intact mitochondrial to reduce a tetrazolium dye to formazan, measured at 72 h post exposure to drug. The loss of mitochondrial function no doubt precedes frank DNA fragmentation. Second, the cell cycle analysis was done at 24 h post-ADR, so even if loss of mitochondrial function and DNA fragmentation occurred simultaneously, the cell cycle assays would show less`damage'. Finally, disruption of mitochondrial function is not speci®c to programmed cell death. It occurs both in apoptosis and necrosis; but we cannot quantitate it and the degree to which SF might protect against non-programmed (necrotic) cell death.
With respect to clonogenic cell survival, this is a much more stringent end-point than MTT dye reduction, which only requires grossly intact mitochondria. Thus, the`survival fraction' measured by MTT assays really re¯ects grossly viable cells at a speci®c point in time (72 h post drug exposure) and does not necessarily re¯ect the ultimate reproductive viability of the cells. The clonogenic survival assay allows 2 weeks for colony growth; during which further damage may be registered as`viable' cells undergo a few abortive divisions before death.
However, the degree of post-ADR repair processes (so-called repair of`potentially lethal damage') may be in¯uenced by the absence or presence of growth factors in the medium, independent of the absence or presence of SF. To avoid this added complication, after exposure to cytotoxic drugs or radiation, all postincubations were performed in standard growth media, the same as the pre-exposure incubations. However, it should be remembered that the main eect of SF occurred during the pre-incubation, rather than during the post-incubation, suggesting the important SFmediated cytoprotective alterations must be present within the cells before the cytotoxin-induced damage is registered.
We investigated potential mechanisms by which SF may protect MDA-MB-453 cells against ADR. These cells contain a deletion in the p53 gene (Runnebaum et al., 1991) , resulting in low levels of p53 that were not up-regulated by ADR. Thus, it is likely that SFmediated protection of this cell line does not occur through a p53-dependent mechanism. One possible mechanism by which cytokines may protect cells against apoptosis is via enhanced cell cycle arrest, Figure 8 Eects of scatter factor and ADR on the cell cycle distribution of MDA-MB-453 cells. Cells were treated as described in Figure 4 legend. Twenty-four hours after ADR treatment, cell cycle analysis was performed by¯ow cytometry of propidium-iodide stained nuclei (see Materials and methods section). Histograms show one experiment representative of three Scatter factor protects against apoptosis S Fan et al which allows increased time for cells to repair DNA damage. This did not appear to be the case for SF, since a similar degree of G2 arrest was observed in cells treated with (SF+ADR) as compared with ADR alone. p21 WAF1/CIP1 is thought to be the major eector of the p53-mediated DNA damage-activated G1 cell cycle check-point (El-Diery et al., 1993) . Consistent with other reports (Gartenhaus et al., 1996) , we found that ADR caused a reduced expression of p21. Pretreatment with SF caused a further decrease in p21 levels. Reduced levels of p21 might be expected to increase the likelihood of apoptosis by forcing G1 cells into S-phase prematurely, causing conversion of singlestrand DNA breaks into double-strand breaks. However, recent studies suggest that p21 may also function to inhibit certain forms of DNA repair (Pan et al., 1995; Umar et al., 1996) and to induce apoptosis (Saeed Sheikh et al., 1995) . Thus SF-induced decreases in p21 levels might contribute to its cytoprotective activity. Alternatively, reduction in p21 levels might be a by-product of other actions of SF, such as stimulation of the proliferation of normal epithelial cell types (see Schecter et al., 1992) .
Our studies of MDA-MB-453 cells have identi®ed several possible apoptosis-induction pathways that may be modulated by SF. Most signi®cantly, SF abrogated the marked ADR-induced decrease in the expression of Bcl-X L , an anti-apoptotic protein that is structurally related to Bcl-2 (Boise et al., 1993) . The dose-response and time course characteristics for SF-mediated increases in the Bcl-X L protein levels ( Figure 7) were consistent with the degrees of protection against apoptosis observed under the same conditions ( Figure  1b) . And Bcl-X L levels were not down-regulated by ADR in MDA-MB-231 cells, consistent with the observations that: (1) MDA-MB-231 cells are somewhat more resistant to ADR than are MDA-MB-453 cells; and (2) SF does not protect MDA-MB-231 cells against ADR-induced apoptosis (Figure 6a ), despite the fact that they express a fully functional c-Met receptor. Thus there is strong circumstantial evidence implicating Bcl-X L as a potentially important target for SF-mediated protection of MDA-MB-453 cells against ADR-induced apoptosis.
Bcl-X L exhibits structural homology with the poreforming domains of bacterial toxins (e.g., diphtheria toxin and colicins), suggesting that it may function to regulate membrane channels (Saeed Sheikh et al, 1995) . Recent studies suggest that Bcl-2, which is localized in the outer mitochondrial membrane, acts by inhibiting release of cytochrome c from mitochondria and preventing activation of caspases, cysteine aspartyl proteases that act as eectors of apoptosis (Muchmore et al., 1996) . Thus, by targeting Bcl-X L , SF might protect cells against apoptosis mediated by mitochondrial alterations.
Bad and Bak are pro-apoptotic members of the Bcl-2 family (Yang et al., 1995; Chittender et al., 1995) . Bad displaces Bax from Bcl-X L , and thereby induces cell death (Yang et al., 1995) . The levels of these proteins in MDA-MB-453 cells were slightly lower in cells treated with (SF+ADR) as compared with ADR alone. SF also induced alterations in the levels of Bax isoforms, although the signi®cance of these changes is not entirely clear. Since Bcl-2 levels were decreased in ADR-treated cells, an SF-induced shift of Bax from an active to an inactive isoform might contribute to the anti-apoptotic phenotype, but further study is required to prove this hypothesis. The net eect of these alterations is to increase the ratio of Bcl-X L /(Bad+Bak) in cells treated with (SF+ADR) relative to ADR alone. This may render cells more resistant to a variety of DNA-damaging agents, by blocking the induction of apoptosis down-stream of DNA damage.
Another major mechanism of induction of apoptosis is the enforced expression of c-Myc in growth factordeprived cells (Packham et al., 1996; Lenehan and Ozer, 1996) . Although it was initially thought that cMyc induced apoptosis was p53-dependent, subsequent study demonstrated the occurrence of c-Myc induced apoptosis in ®broblasts transfected with SV40 T antigen to ablate p53 function (Lenehan and Ozer, 1996) . It is not certain which c-Myc target genes are required for induction of apoptosis, but recent studies have identi®ed two possible candidates: ornithine decarboxylase and the CDC25A cell cycle phosphatase (Packham et al., 1996; Galaktonor et al., 1996) . We found that while SF and ADR by themselves each caused an increase in c-Myc protein expression, pretreatment with SF blocked the ADR-induced increase in c-Myc protein levels. Since the ADR-treated cells were at least partially growth arrested, the reduced levels of c-Myc in the SF-treated cells might have contributed to the observed cytoprotective eect of SF.
Other members of the c-Myc transcriptional network can regulate both c-Myc transcriptional activation and apoptosis. Formation of c-Myc : Max heterodimers promotes c-Myc transcriptional activity. On the other hand, the association of Mad with Max inhibits c-Myc activity by formation of a ternary complex with the transcriptional repressor mSin3. Thus, Max can participate in both transcriptional activation and repression of c-Myc responsive genes (Hurlin et al, 1993 (Hurlin et al, , 1994 . Under basal conditions, MDA-MB-453 cells expressed predominantly the p21Max S isoform of Max. Treatment with ADR induced an increase in the levels of Max S as well as appearance of a band corresponding to p22Max L . Interestingly, over-expression of the Max L isoform may itself induce apoptosis by a c-Myc independent mechanism that involves the binding of homodimers of Max L to DNA (Zhang et al., 1997) . Thus, the induction of Max L may have contributed to the ADR-induced apoptosis. Cells treated with (SF+ADR) exhibited two bands with slightly higher M r values than the p22Max L band, consistent with phosphorylated forms of Max L . The signi®cance of this ®nding is unclear. However, a recent study suggests that phosphorylation of Max may inhibit binding of Max homodimers to DNA (Berberich and Cole, 1992) , an eect that might serve to block apoptosis (Zhang et al., 1997) .
Pre-treatment with SF blocked ADR-induced decreases in the Mad2 (also known as Mxi1) and Mad3. Although this eect was relatively modest, the net result of SF-treatment would be to further reduce the ratio of c-Myc/Mad in ADR-treated cells, which is expected to inhibit c-Myc activated transcription by shifting Max from Myc : Max to Mad : Max complexes (Hurlin et al., 1993 (Hurlin et al., , 1994 . The reduction of transcriptional activation of c-Myc target genes coupled with decreased binding of Max homodimers to DNA may then prevent cells from entering into apoptosis. Alternatively, these alterations may be a secondary eect or a by-product of other actions of SF.
It seems unclear, however, that if SF-induced alterations in the c-Myc transcriptional network contribute to protection, reduced expression of c-Myc by itself is insucient for protection against apoptosis. Thus, SF blocked the ADR-induced increase in c-Myc protein levels in both MDA-MB-453 and MDA-MB-231 cells; but the MDA-MB-231 cells were not protected against ADR, indicating that some additional alterations are required for protection. Further study is required to fully assess the functional signi®cance of these SF-induced alterations in the levels of c-Myc transcriptional network proteins.
Recently, BRCA1 has been implicated in the regulation of apoptosis. Over-expression of BRCA1 induced apoptosis ; while inhibition of BRCA1 using antisense RNA rendered cells resistant to the induction of apoptosis by a calcium ionophore . We found that MDA-MB-453 cells treated with (SF+ADR) cells expressed signi®cantly lower levels of the 220 kDa BRCA1 protein than did cells treated with ADR alone. Thus, the reduced levels of BRCA1 might have contributed to the protection of SF-treated cells against ADR. As was true for c-Myc, the eects of treatment with (SF+ADR) on BRCA1 were not the same as might be predicted from a summation of the eects of SF alone plus ADR alone. These observations plus the requirement for a prolonged exposure to SF for cytoprotection suggest that SF may act, in part, bỳ pre-conditioning' cells so that their biochemical responses render them generally more resistant to the induction of apoptosis.
In summary, our studies indicate that SF can inhibit apoptosis induced by DNA-damaging agents, including adriamycin, therapeutic X-rays and UV radiation. The mechanism of SF-mediated protection of MDA-MB-453 human breast cancer cells against ADR-induced apoptosis is complex and may involve inhibition of several distinct pathways for the activation of a cell death program. However, our ®ndings do suggest that SF treatment targets the anti-apoptotic mitochondrial pore-forming protein Bcl-X L as one component of the protective mechanism. These ®ndings imply that the accumulation of SF within human breast cancers may contribute to the development of a chemoresistant or radioresistant phenotype.
Materials and methods
Sources of reagents and antibodies
Recombinant human two-chain SF and the SF a-chain peptide NK1 were provided by Dr Ralph Schwall, Genentech., Inc. (South San Francisco, CA). Adriamycin (ADR) was purchased from Sigma Chemical Co. (St. Louis, MO). The primary antibodies used for Western blotting were as follows: p53 (Ab-2, pAb1801), p21
(H-209) and a-actin (I-19). All primary and secondary antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) except for the p53, p21 WAF/CIP1 , and Bak antibodies, which were purchased from Oncogene Research Products (Cambridge, MA). MTT dye (thiazotyl blue) was obtained from Sigma.
Cell lines and culture
Two lines of human breast carcinoma cells (MDA-MB-453 and MDA-MB-231) and Madin-Darby canine kidney (MDCK) epithelial cells were obtained from the American Type Culture Collection (Rockville, MD). EMT6 mouse mammary tumor cells have been maintained by alternate in vitro and in vivo passage in isogeneic Balb/c-Rw host mice by one of us (SR). All cell lines were cultured using standard techniques in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal calf serum, 5 mM glutamine, 100 mg/ml streptomycin and 100 units/ml penicillin (all from BioWhittaker, Walkersville, MD).
Treatment of cells with DNA-damaging agents
For most experiments, subcon¯uent proliferating cultures in 100 mm plastic Petri dishes were pre-incubated+SF (100 ng/ml 6 48 h) and then sham-treated or treated with ADR (5 mM 6 1 h). After exposure to ADR, cultures were washed twice to remove the ADR and then incubated in fresh medium (again, without or with 100 ng/ml of SF) at 378C for 24 h. Cells were then harvested for assays of DNA fragmentation or for Western blotting. For Xirradiation experiments, cells were treated using 6 MeV photons from a Varian Clinac 2300 linear accelerator at a dose rate of 6 Gy/min. For ultraviolet (UV) irradiation experiments, the culture medium was removed, cells were washed with phosphate-buered saline (PBS), and the saline was aspirated prior to irradiation. Cultures were exposed to 10 J/m 2 of UV-C light (254 nm) using a Philips UV lamp. Fresh medium was then re-introduced, and the cells were post-incubated for 24 h. UV and X-radiation were delivered at room temperature, while ADR treatment was done at 378C.
DNA fragmentation assays
DNA fragmentation was assessed by agarose gel electrophoresis (Hermann et al., 1994) and by¯ow cytometry (Fan et al., 1994) . For DNA electrophoresis, cells were harvested by centrifugation, washed twice in PBS and then resuspended in 200 ml of lysis buer (50 mM Tris-HCl, pH 7.5, 0.1 M EDTA, and 1% NP-40). The supernatants were incubated with 1% SDS and 5 mg/ml of RNase A for 2 h at 378C and then treated overnight with 2.5 mg/ml of proteinase K at 568C. DNA was precipitated with 1/2 volume of 10 M ammonium acetate and 2.5 volumes of 95% ethanol. Precipitated DNA was dissolved in gel loading buer and then analysed by electrophoresis on a 1.5% agarose gel containing 0.1 mg/ml of ethidium bromide for visualization of`DNA ladders'. For¯ow cytometry, the cells were pelleted by centrifugation, washed with PBS, and ®xed overnight in 5 ml of 75% ethanol at 48C. The ®xed cells were pelleted twice in ice-cold PBS and resuspended in PBS containing 500 unit/ml RNase A and 50 mg/ml of propidium iodide (Sigma). Cell cycle analysis was performed on a Becton-Dickinson¯uorescence-activated cell sorter at the Albert Einstein College of Medicine (Bronx, NY).
Cell viability, clonogenic survival, and lung colony formation assays Cell viability was evaluated using the MTT reduction conversion assay, as described before (Alley et al, 1988 ).
This assay is based on the the ability of viable cells to convert MTT, a soluble tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide] into an insoluble formazan precipitate, which is quantitated by spectrophotometry following solubilization in dimethyl sulfoxide. Brie¯y, subcon¯uent proliferating cells in 96-well dishes were pre-treated + SF (100 ng/ml 6 48 h) and then treated with dierent doses of ADR for 1 h. Cells were post-incubated for 5 days, after which the cells were solubilized and absorbance readings were taken using a Dynatech 96-well spectrophotometer. The amount of MTT dye reduction was calculated based on the absorbance at 570 nm. Cell`survival' was expressed as the amount of dye reduction relative to that of untreated control cells.
To assay clonogenic survival, subcon¯uent proliferating cultures of cells were incubated + SF (100 ng/ml 6 48 h); then + ADR (5 mM 6 1 h). Cultures were then washed, incubated in fresh media for 24 h, harvested using trypsin and seeded into 100 mm Petri dishes at low density (300, 1000, and 2500 cells per dish) in fresh medium, to allow colony formation. Dishes were incubated for 2 weeks; and then the cells were stained with crystal violet for colony counts. Colonies of 520 cells were scored as survivors.
Lung colony formation was assayed as described before (Rosen et al., 1994a) . EMT6 cells were treated + SF and +ADR in vitro, as above; detached using trypsin; suspended in fresh medium; counted using a Coulter counter; and injected into the tail veins of isogeneic 2.5 ± 3.5 month old Balb/c-Rw mice (54 animals per treatment group). Cell numbers injected were 2000 cells/animal for non-ADR treated cells and 20 000 cells/animal for ADR-treated cells. Animals were killed after 14 days; the lungs were ®xed with Bouin's solution; and the number of surface lung colonies was counted in a`blinded' fashion.
Western blotting analysis
Western immunoblotting was performed as described previously (Fan et al., 1995) . Brie¯y, cells were centrifuged, washed with PBS, and lysed at 08C for 30 min in 100 ± 200 ml/100 mm dish of lysis buer (1% NP-40, in PBS containing 2 mM 4-(2-aminoethylbenzensulfonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml aptotinin, 10 mM NaF, 1 mM Na orthovandate and 5 mM Na pyrophosphate). Protein concentrations were determined using the Bio-Rad dye-binding microassay (Bio-Rad, Hercules, CA); and 100 mg protein/lane was electrophoresed on 12% SDS-polyacrylamide gels (8% for high M r proteins) after boiling for 5 min in Laemmli sample buer. Proteins were transferred to Imobilon membranes (Millipore, Bedford, MA) by electroblotting. Equal protein loading was con®rmed by fast green staining of membrane and by immunoblotting with a polyclonal antibody against a-actin. Colored markers were used as protein size standards (Bio-Rad). After electroblotting, the membranes were blocked in PBS-Tween blocking buer containing 5% non-fat dry milk, washed with PBS-Tween buer, and incubated with the primary antibody diluted in blocking buer for 1 h. Membranes were then washed, incubated with second antibody (1 : 3000) in blocking buer for 1 h and re-washed. Blotted proteins were detected using the enhanced chemiluminescence detection system (Amersham Life Sciences). Each Western blotting experiment was repeated at least twice.
Abbreviations ADR, adriamycin; BRCA1, breast and ovary cancer susceptibility gene 1; DMEM, Dulbecco's Modi®ed Eagle's Medium; MDCK, Madin-Darby canine kidney epithelial cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide; PBS, phosphate-buered saline; SF, scatter factor; UV, ultraviolet.
